Phase 1 Hepatic Impairment Clinical Trials

21 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Phase 1 Hepatic Impairment Clinical Trials

What is a Phase 1 trial?

A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib

Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment

Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function

A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)

Phase 1 Open-Label Study of Radiprodil Pharmacokinetics, Safety, and Tolerability in Hepatically Impaired Participants

Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment

Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement

An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage